Amarin added that this unnamed PBM accounted for almost 25% of the U.S. Vascepa prescription volumes generated from this channel.However, the decision will not impact PBM's Medicare Part D ...

He will be responsible for leading Amarin’s global finance organization and will report directly to the Company’s Chief Executive Officer, Aaron Berg. Most recently, Mr. F Amarin (AMRN ...

Amarin is on course to significantly increase the number of patients eligible for treatment with its purified fish oil drug Vascepa after an FDA advisory committee voted in favour of an expanded ...

Amarin (NASDAQ:AMRN – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Monday. Amarin Stock Down 0.3 % Shares of NASDAQ AMRN ...

Amarin said Peter Fishman has been appointed its new finance chief, effective immediately. The company said Fishman most recently served as its global controller and principal financial and ...

Amarin said in a statement that this is the first drug in the class to be recommended by NICE for cardiovascular risk reduction. The final guidance is expected to be published on 20 July.

Amarin Corporation has appointed Peter Fishman as Chief Financial Officer, effective immediately. Fishman, who previously served as the Company’s Global Controller and principal financial and ...

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Amarin (AMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings ...